Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-Analysis
BackgroundLenvatinib has shown promising efficacy in targeted therapies that have been tested to treat anaplastic thyroid carcinoma (ATC) in both preclinical and clinical studies. The aim of this study was to evaluate the efficacy and safety of lenvatinib in the treatment of patients with ATC.Method...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.920857/full |
| _version_ | 1811229173776121856 |
|---|---|
| author | Dongmei Huang Jinming Zhang Xiangqian Zheng Ming Gao Ming Gao Ming Gao |
| author_facet | Dongmei Huang Jinming Zhang Xiangqian Zheng Ming Gao Ming Gao Ming Gao |
| author_sort | Dongmei Huang |
| collection | DOAJ |
| description | BackgroundLenvatinib has shown promising efficacy in targeted therapies that have been tested to treat anaplastic thyroid carcinoma (ATC) in both preclinical and clinical studies. The aim of this study was to evaluate the efficacy and safety of lenvatinib in the treatment of patients with ATC.MethodsPubMed, the Cochrane Library, Embase, and ClinicalTrials.gov were searched for potential eligible studies from inception to February 1, 2022. The outcomes included partial response (PR), stable disease (SD), disease control rate (DCR), median progression-free survival (mPFS), and median overall survival (mOS). Effect sizes for all pooled results were presented with 95% CIs with upper and lower limit.ResultsTen studies met the inclusion criteria. The aggregated results showed that the pooled PR, SD, and DCR were 15.0%, 42.0%, and 63.0%, respectively. The pooled mPFS and mOS were 3.16 (2.18–5.60) months and 3.16 (2.17–5.64) months, respectively. Furthermore, PFS rate at 3 months (PFSR-3m), PFSR-6m, PFSR-9m, PFSR-12m, and PFSR-15m were 52.0%, 22.5%, 13.9%, 8.4%, and 2.5%, respectively. Meanwhile, the 3-month OS rate (OSR-3m), OSR-6m, OSR-9m, OSR-12m, and OSR-15m were 64.0%, 39.3%, 29.7%, 18.9%, and 14.2%, respectively. The most common adverse events (AEs) of lenvatinib were hypertension (56.6%), proteinuria (32.6%), and fatigue (32%).ConclusionsThis meta-analysis showed that lenvatinib has meaningful antitumor activity, but limited clinical efficacy in ATC.Systematic Review RegistrationPROSPERO [https://www.crd.york.ac.uk/PROSPERO/], identifier [CRD42022308624]. |
| first_indexed | 2024-04-12T10:10:35Z |
| format | Article |
| id | doaj.art-fe73fa2329e545ac890cd4b176146e55 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-04-12T10:10:35Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-fe73fa2329e545ac890cd4b176146e552022-12-22T03:37:20ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922022-06-011310.3389/fendo.2022.920857920857Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-AnalysisDongmei Huang0Jinming Zhang1Xiangqian Zheng2Ming Gao3Ming Gao4Ming Gao5Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, ChinaDepartment of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, ChinaDepartment of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, ChinaDepartment of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, ChinaDepartment of Thyroid and Breast Surgery, Tianjin Union Medical Center, Tianjin, ChinaTianjin Key Laboratory of General Surgery Inconstruction, Tianjin Union Medical Center, Tianjin, ChinaBackgroundLenvatinib has shown promising efficacy in targeted therapies that have been tested to treat anaplastic thyroid carcinoma (ATC) in both preclinical and clinical studies. The aim of this study was to evaluate the efficacy and safety of lenvatinib in the treatment of patients with ATC.MethodsPubMed, the Cochrane Library, Embase, and ClinicalTrials.gov were searched for potential eligible studies from inception to February 1, 2022. The outcomes included partial response (PR), stable disease (SD), disease control rate (DCR), median progression-free survival (mPFS), and median overall survival (mOS). Effect sizes for all pooled results were presented with 95% CIs with upper and lower limit.ResultsTen studies met the inclusion criteria. The aggregated results showed that the pooled PR, SD, and DCR were 15.0%, 42.0%, and 63.0%, respectively. The pooled mPFS and mOS were 3.16 (2.18–5.60) months and 3.16 (2.17–5.64) months, respectively. Furthermore, PFS rate at 3 months (PFSR-3m), PFSR-6m, PFSR-9m, PFSR-12m, and PFSR-15m were 52.0%, 22.5%, 13.9%, 8.4%, and 2.5%, respectively. Meanwhile, the 3-month OS rate (OSR-3m), OSR-6m, OSR-9m, OSR-12m, and OSR-15m were 64.0%, 39.3%, 29.7%, 18.9%, and 14.2%, respectively. The most common adverse events (AEs) of lenvatinib were hypertension (56.6%), proteinuria (32.6%), and fatigue (32%).ConclusionsThis meta-analysis showed that lenvatinib has meaningful antitumor activity, but limited clinical efficacy in ATC.Systematic Review RegistrationPROSPERO [https://www.crd.york.ac.uk/PROSPERO/], identifier [CRD42022308624].https://www.frontiersin.org/articles/10.3389/fendo.2022.920857/fullanaplastic thyroid carcinomalenvatinibefficacysafetymeta-analysis |
| spellingShingle | Dongmei Huang Jinming Zhang Xiangqian Zheng Ming Gao Ming Gao Ming Gao Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-Analysis Frontiers in Endocrinology anaplastic thyroid carcinoma lenvatinib efficacy safety meta-analysis |
| title | Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-Analysis |
| title_full | Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-Analysis |
| title_fullStr | Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-Analysis |
| title_full_unstemmed | Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-Analysis |
| title_short | Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-Analysis |
| title_sort | efficacy and safety of lenvatinib in anaplastic thyroid carcinoma a meta analysis |
| topic | anaplastic thyroid carcinoma lenvatinib efficacy safety meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2022.920857/full |
| work_keys_str_mv | AT dongmeihuang efficacyandsafetyoflenvatinibinanaplasticthyroidcarcinomaametaanalysis AT jinmingzhang efficacyandsafetyoflenvatinibinanaplasticthyroidcarcinomaametaanalysis AT xiangqianzheng efficacyandsafetyoflenvatinibinanaplasticthyroidcarcinomaametaanalysis AT minggao efficacyandsafetyoflenvatinibinanaplasticthyroidcarcinomaametaanalysis AT minggao efficacyandsafetyoflenvatinibinanaplasticthyroidcarcinomaametaanalysis AT minggao efficacyandsafetyoflenvatinibinanaplasticthyroidcarcinomaametaanalysis |